Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Illumina, Inc. - Common Stock (NQ:ILMN)

100.11 +0.02 (+0.02%)
Streaming Delayed Price Updated: 4:00 PM EDT, Aug 15, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Illumina, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
23 24 Next >
Icahn Hedge Fund's Q2 Moves: Centuri Stake Soars, JetBlue Held, 2 Positions Exited
Carl Icahn's 13F shows concentrated equity book, with top 10 holdings making up 98.76%. Notable changes in non-house names like CTRI and IFF. 
Via Benzinga
NICE Stock Stops Being Nice, Has A Bearish Breakdown
NICE Ltd. has ended a 15-year trend with a bearish breakdown, signaling extended downside risk. Here's what the Adhishthana Principles reveal... 
Via Benzinga
Clover Health, Surgery Partners, Illumina, Bruker, and Supernus Pharmaceuticals Shares Skyrocket, What You Need To Know
A number of stocks jumped in the afternoon session after markets continued to rally amid growing speculation of an impending interest rate cut by the Federal Reserve. Following a favorable Consumer... 
Via StockStory
Topics Economy
What Does the Market Think About Illumina?
 
Via Benzinga
Earnings Scheduled For July 31, 2025
 
Via Benzinga
Illumina’s Q2 Earnings Call: Our Top 5 Analyst Questions
Illumina’s second quarter performance in 2025 was met with a significant negative market reaction, as shares declined in response to ongoing revenue contraction and sharply lower operating margins.... 
Via StockStory
Topics Earnings World Trade
ILMN Q2 Deep Dive: Clinical Demand Cushions Revenue Decline Amid Research Weakness and Margin Pressures
Genomics company Illumina (NASDAQ:ILMN) reported Q2 CY2025 results beating Wall Street’s revenue expectations, but sales fell by 3% year on year to $1.06 billion. Its non-GAAP profit of $1.19 per share... 
Via StockStory
Centene, RadNet, Evolent Health, Illumina, and Charles River Laboratories Shares Are Soaring, What You Need To Know
A number of stocks jumped in the morning session after positive inflation data fueled hopes for an interest rate cut by the Federal Reserve. 
Via StockStory
Topics Bonds Economy Stocks
Illumina Settles With DOJ, Veterans To End Whistleblower Lawsuit
Illumina will pay $9.8 million to settle allegations it sold genomic systems with cybersecurity flaws to U.S. agencies. A whistleblower will receive $1.9 million. 
Via Benzinga
Topics Whistleblower
PacBio (PACB) Q2 Earnings Report Preview: What To Look For
Genomics company Pacific Biosciences of California (NASDAQ:PACB) will be announcing earnings results this Thursday afternoon. Here’s what to expect. 
Via StockStory
Topics Artificial Intelligence World Trade
Earnings To Watch: 10x Genomics (TXG) Reports Q2 Results Tomorrow
Biotech company 10x Genomics (NASDAQ:TXG) will be reporting results this Thursday after market hours. Here’s what to expect. 
Via StockStory
Topics Artificial Intelligence Economy World Trade
Illumina (ILMN) Q2 2025 Earnings Call Transcript
Via The Motley Fool
Topics Earnings
Cathie Wood's Ark Invest Loads Up On Coinbase, Roku, Illumina, And Bitmine Immersion
Cathie Wood-led Ark Invest made significant trades in COIN, ROKU, ILMN, and BMNR. They also bought PD and SOFI, sold KTOS and RBLX. 
Via Benzinga
Illumina (ILMN) Q2 EPS Jumps 9%
Via The Motley Fool
Why Illumina (ILMN) Shares Are Falling Today
Shares of genomics company Illumina (NASDAQ:ILMN) fell 6.1% in the afternoon session as investors reacted to its second-quarter earnings report, where a year-over-year revenue decline overshadowed... 
Via StockStory
Topics Artificial Intelligence World Trade
These Analysts Boost Their Forecasts On Illumina Following Upbeat Results
 
Via Benzinga
Illumina: A 5.2 Rating Amid Challenges and Opportunities
Via The Motley Fool
Illumina Inc (NASDAQ:ILMN) Q2 2025 Earnings: Mixed Results with Revenue Miss and EPS Beat
Illumina's Q2 2025 earnings show mixed results: revenue missed estimates at $1.059B (-3% YoY), but EPS beat at $1.19. Shares dipped 1.18% post-report. 
Via Chartmill
Illumina (NASDAQ:ILMN) Surprises With Q2 Sales
Genomics company Illumina (NASDAQ:ILMN) beat Wall Street’s revenue expectations in Q2 CY2025, but sales fell by 3% year on year to $1.06 billion. Its non-GAAP profit of $0.36 per share was 64.4% below... 
Via StockStory
Illumina (ILMN) To Report Earnings Tomorrow: Here Is What To Expect
Genomics company Illumina (NASDAQ:ILMN) will be reporting earnings this Thursday afternoon. Here’s what to expect. 
Via StockStory
Topics Artificial Intelligence
Illumina (ILMN) Stock Is Up, What You Need To Know
Shares of genomics company Illumina (NASDAQ:ILMN) jumped 3.7% in the pre-market session after analysts at Robert W. Baird increased their price target on the life sciences company's stock to $105.00.... 
Via StockStory
Topics Artificial Intelligence
12 Analysts Assess Illumina: What You Need To Know
 
Via Benzinga
1 Profitable Stock with Exciting Potential and 2 We Question
Not all profitable companies are built to last - some rely on outdated models or unsustainable advantages. Just because a business is in the green today doesn’t mean it will thrive tomorrow. 
Via StockStory
Illumina Stock: What Went Wrong And Why It's Best To Stay Away
According to the Adhishthana Principles, Illumina stock may remain under pressure for over 18 years — here's why. 
Via Benzinga
Why Illumina (ILMN) Shares Are Falling Today
Shares of genomics company Illumina (NASDAQ:ILMN) fell 4.2% in the morning session after a Citi analyst downgraded the stock to 'Sell' from 'Neutral' and lowered the price target. 
Via StockStory
Topics Government World Trade
Where Illumina Stands With Analysts
 
Via Benzinga
Illumina (ILMN) Stock Trades Down, Here Is Why
Shares of genomics company Illumina (NASDAQ:ILMN) fell 3.6% in the afternoon session after the major indices pulled back (Nasdaq -0.8%, S&P 500 -0.77%), largely due to escalating concerns surrounding... 
Via StockStory
Topics Artificial Intelligence Government Stocks
5 Must-Read Analyst Questions From Illumina’s Q1 Earnings Call
Illumina’s first quarter results reflected ongoing challenges in the global genomics market, as the company’s performance fell short of market expectations, prompting a negative reaction from... 
Via StockStory
Topics Earnings World Trade
SomaLogic Acquisition Marks Next Step In Illumina's Advanced Biomarker Push
Illumina will acquire SomaLogic to expand in proteomics, adding new revenue streams and accelerating tech development in multiomics. 
Via Benzinga
1 of Wall Street’s Favorite Stock to Target This Week and 2 to Brush Off
Wall Street is overwhelmingly bullish on the stocks in this article, with price targets suggesting significant upside potential. However, it’s worth remembering that analysts rarely issue sell ratings,... 
Via StockStory
Topics Energy
< Previous 1 2 3 4 5 6 7 8 9
...
23 24 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.